Blueprint Medicines Corp Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash lease expense
Stock-based compensation
Non-cash interest expense
Non-cash customer consideration
Acquired in-process research and development
Non-cash debt extinguishment gain
Net (accretion of discount) amortization of premium on investments
Other
Changes in assets and liabilities:
Accounts receivable
Unbilled accounts receivable
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Other long-term liabilities
Deferred revenue
Operating lease liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Purchase of in-process research and development asset, net of cash acquired
Purchases of investments
Maturities of investments
Other
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from at-the-market offerings, net of issuance costs
Net proceeds from stock option exercises and employee stock purchase plan
Proceeds from issuance of common stock related to collaboration agreement
Other
Net proceeds from term loan facility
Net proceeds from the sale of future royalties and revenues
Principal payments for financing arrangements
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at end of period
Supplemental cash flow information
Cash paid for interest
Property and equipment purchases unpaid at period end
Cash paid (refunds received) for taxes, net

Comments